GGrantIndex
← Leaderboards

Yolanda Sanchez

University Of Cincinnati

$7,720,519
Attributed
$9,545,518
Total exposure
8
Grants
7
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $3.5M · FY200525
$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$19,676,868 · 9

By mechanism

P30$13,259,505 · 5
R01$5,438,585 · 2
U01$590,988 · 1
R21$387,790 · 1

Top collaborators

Most similar at University Of Cincinnati

Same institution · by research overlap

Others in their field

Top investigators on “Universities

Research focus

UniversitiesMalignant NeoplasmsLaboratoriesCancer CenterMemberResource SharingCancer Center Support GrantResourcesResearch PersonnelResearch InstituteNew MexicoMeetingsCancer PreventionProgramsGrantMissionNci Center For Cancer ResearchMexicanLeadershipFundingRespiratoryCommunitiesExtramural ActivitiesFaculty

Grant awards (50)

University of New Mexico Cancer Center Support Grant$2,300,943
P30 · FY2025 · CA · contact PI
Leadership, Planning and Evaluation$384,236
P30 · FY2025 · CA · contact PI
Developmental Funds$306,742
P30 · FY2025 · CA · contact PI
Cancer Center Administration$193,205
P30 · FY2025 · CA · contact PI
Precarity in Gynecologic Oncology: A mixed methods study addressing intersections of uncertainty, marginalization, and cancer.$190,625
P30 · FY2025 · CA · contact PI
Early Career Cancer Clinical Investigator Award (ECIA)$60,000
P30 · FY2025 · CA · contact PI
University of New Mexico Cancer Center Support Grant$2,300,943
P30 · FY2024 · CA · contact PI
Leadership, Planning and Evaluation$384,236
P30 · FY2024 · CA · contact PI
Developmental Funds$306,742
P30 · FY2024 · CA · contact PI
Cancer Center Administration$193,205
P30 · FY2024 · CA · contact PI
Precarity in Gynecologic Oncology: A mixed methods study addressing intersections of uncertainty, marginalization, and cancer.$190,625
P30 · FY2024 · CA · contact PI
The impact of microplastics exposure across lifespan on human colons$100,000
P30 · FY2024 · CA · contact PI
Early Career Cancer Clinical Investigator Award (ECIA)$60,000
P30 · FY2024 · CA · contact PI
University of New Mexico Cancer Center Support Grant$2,300,943
P30 · FY2023 · CA · contact PI
Leadership, Planning and Evaluation$384,237
P30 · FY2023 · CA · contact PI
University of New Mexico Cancer Center Support Grant$326,328
P30 · FY2023 · CA · contact PI
Developmental Funds$306,744
P30 · FY2023 · CA · contact PI
Cancer Center Administration$193,205
P30 · FY2023 · CA · contact PI
University of New Mexico Cancer Center Support Grant$2,300,943
P30 · FY2022 · CA · contact PI
Targeting Tumors with NF1 Loss$531,751
R01 · FY2019 · NS · contact PI
Targeting Tumors with NF1 Loss$541,146
R01 · FY2018 · NS · contact PI
Targeting Tumors with NF1 Loss$544,581
R01 · FY2017 · NS · contact PI
Targeting Tumors with NF1 Loss$547,736
R01 · FY2016 · NS · contact PI
Targeting Tumors with NF1 Loss$572,285
R01 · FY2015 · NS · contact PI
MOLECULAR BIOLOGY SHARED RESOURCE$124,348
P30 · FY2014 · CA · contact PI
MOLECULAR BIOLOGY SHARED RESOURCE$64,303
P30 · FY2013 · CA · contact PI
MOLECULAR BIOLOGY SHARED RESOURCE$68,436
P30 · FY2012 · CA · contact PI
MOLECULAR BIOLOGY SHARED RESOURCE$68,107
P30 · FY2011 · CA · contact PI
Identification of Drug Targets for NF1$205,673
R21 · FY2010 · NS · contact PI
MOLECULAR BIOLOGY SHARED RESOURCE$77,565
P30 · FY2010 · CA · contact PI
Identification of Drug Targets for NF1$182,117
R21 · FY2009 · NS · contact PI
Dissection of the DNA damage checkpoint pathways$151,496
R01 · FY2009 · CA · contact PI
MOLECULAR BIOLOGY SHARED RESOURCE$72,844
P30 · FY2009 · CA · contact PI
Dissection of the DNA damage checkpoint pathways$307,019
R01 · FY2008 · CA · contact PI
Dissection of the DNA damage checkpoint pathways$307,019
R01 · FY2007 · CA · contact PI
Dissection of the DNA damage checkpoint pathways$316,188
R01 · FY2006 · CA · contact PI
Dissection of the DNA damage checkpoint pathways$166,210
R01 · FY2005 · CA
Dissection of the DNA damage checkpoint pathways$145,893
R01 · FY2005 · CA
DISSECTION OF THE DNA DAMAGE CHECKPOINT PATHWAYS$136,056
R01 · FY2004 · CA
DISSECTION OF THE DNA DAMAGE CHECKPOINT PATHWAYS$282,317
R01 · FY2003 · CA
DISSECTION OF THE DNA DAMAGE CHECKPOINT PATHWAYS$41,945
R01 · FY2003 · CA
DISSECTION OF THE DNA DAMAGE CHECKPOINT PATHWAYS$288,809
R01 · FY2002 · CA
Chk1 and cell cycle arrest in response to DNA Damage$196,996
U01 · FY2002 · ES
Chk1 and cell cycle arrest in response to DNA Damage$196,996
U01 · FY2002 · ES
Chk1 and cell cycle arrest in response to DNA Damage$196,996
U01 · FY2002 · ES
DISSECTION OF THE DNA DAMAGE CHECKPOINT PATHWAYS$41,614
R01 · FY2002 · CA
Checkpoint pathways as targets for drug discovery$8,260
R01 · FY2002 · CA
DISSECTION OF THE DNA DAMAGE CHECKPOINT PATHWAYS$266,110
R01 · FY2001 · CA
Chk1 and cell cycle arrest in response to DNA Damage$0
U01 · FY2001 · ES
DISSECTION OF THE DNA DAMAGE CHECKPOINT PATHWAYS$242,150
R01 · FY2000 · CA